Pfizer has again been sued over a deal it struck years ago that delayed generic competition to Lipitor, still the best-selling drug of all time. The lawsuit comes from national pharmacy chain CVS, which claims the deal cost it hundreds of millions of dollars.
The 101-page complaint, filed last week in federal court in New Jersey, names Pfizer and Indian drugmaker Ranbaxy Laboratories, which was bought out in 2015 by Sun Pharmaceutical.
The complaint accuses Pfizer of striking a pay-for-delay deal with the generics maker that kept Lipitor copycats off the market for 20 months, depriving consumers of billions of dollars in savings and costing CVS hundreds of millions in extra costs. Because Ranbaxy had six months of exclusivity through its so-called first-to-file status, other generics could not come into the market until the generics maker launched its own copy. Lipitor had 2010 US sales of US$5.3 billion.
Full Content: Law 360
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
FCC Set to Reinstate Net Neutrality Rules Today
Apr 25, 2024 by
CPI
Chamber of Commerce Sues to Overturn FTC Non-Compete Ban
Apr 24, 2024 by
CPI
FTC Chief Warns of Healthcare Price Fixing Risks Amid Tech Advancements
Apr 24, 2024 by
CPI
Amazon’s Investment in Anthropic Faces Antitrust Scrutiny
Apr 24, 2024 by
CPI
Italian Antitrust Authority Fines Amazon €10 Million for Unfair Trade Practices
Apr 24, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Economics of Criminal Antitrust
Apr 19, 2024 by
CPI
Navigating Economic Expert Work in Criminal Antitrust Litigation
Apr 19, 2024 by
CPI
The Increased Importance of Economics in Cartel Cases
Apr 19, 2024 by
CPI
A Law and Economics Analysis of the Antitrust Treatment of Physician Collective Price Agreements
Apr 19, 2024 by
CPI
Information Exchange In Criminal Antitrust Cases: How Economic Testimony Can Tip The Scales
Apr 19, 2024 by
CPI